Sun Pharmaceutical Industries reported a 15.1% YoY increase in revenue to ₹154,691 million for Q3FY26. Net profit rose by 16.0% to ₹33,688 million. The company declared an interim dividend of ₹11.00 per share. Growth was driven by branded businesses in India, emerging markets, and global innovative medicines. The US formulation sales were up 0.6% to US$ 477 million.
Financial Performance
Sun Pharma’s consolidated sales for Q3FY26 reached ₹154,691 million, representing a 15.1% increase compared to the previous year. The company’s net profit stood at ₹33,688 million, up by 16.0% YoY.
Dividend Announcement
The Board of Directors has declared an interim dividend of ₹11.00 per equity share for the financial year 2025-26. The record date for determining entitlement to the dividend is February 5, 2026. The dividend will be paid on or before February 16, 2026.
Segmental Performance
India Formulation sales grew by 16.2% to ₹49,986 million, accounting for 32.3% of total sales. For the nine months, these sales reached ₹144,545 million, a growth of 13.7%.
US Formulation sales increased slightly by 0.6% to US$ 477 million. These sales account for approximately 27.5% of total consolidated sales. Nine-month sales totaled US$ 1,445 million.
Emerging Markets (EM) formulation sales grew by 21.6% to US$ 337 million, accounting for 19.4% of total sales. Nine-month sales were US$ 960 million, a growth of 12.4%.
Rest of World (RoW) formulation sales grew by 14.5% to US$ 296 million, accounting for 17.1% of total sales. Nine-month sales reached US$ 749 million, a growth of 15.8%.
Global Innovative Medicines sales reached US$ 423 million, including a milestone income of US$ 55 million. Excluding the milestone income, these sales grew by 13.2% and accounted for 21.2% of sales. For the nine months, sales were US$ 1,067 million, up by 15.7%.
R&D Investments
The company’s R&D expenditure for the quarter amounted to ₹8,928 million, representing 5.8% of sales.
Source: BSE
